The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury

Recruiting now · Phase 4

Conditions studied: Cognitive Impairment After Brain Injury

In brief

This study will conduct a single-center clinical trial to explore the initial therapeutic effect of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment.

Key facts

Study ID

NCT06704334

Run by

Wanbangde Pharmaceutical Group Co., LTD

People needed

50

Starts

2024-04-01

Expected to finish

2026-12-31

Last updated by the study team

2024-12-11

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be over 18 years old
• Residual cognitive impairment due to brain injury
• No previous history of brain-related diseases except this one

You may not qualify if…

• The patient had severe underlying disease and unstable vital signs
• The patient was complicated with consciousness disorder and could not cooperate with cognitive function assessment ③ Allergic to drugs or contraindications in drug use ④ There are contraindications of median nerve electrical stimulation

Where it is running

• The Ganzhou City People's Hospital — Ganzhou, Jiangxi, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.